1. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide;Decristoforo;J. Nucl. Med.,2000
2. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives;Decristoforo;Eur. J. Nucl. Med.,2000
3. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors;Gabriel;J. Nucl. Med.,2003
4. Kowalsky, R.J., Falen, S.W., 2004. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine, second ed. American Pharmacist Association, pp. 71–98.
5. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients;Krenning;Eur. J. Nucl. Med.,1993